Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01770002
Other study ID # 265161
Secondary ID
Status Completed
Phase N/A
First received January 15, 2013
Last updated April 15, 2015
Start date January 2012
Est. completion date September 2014

Study information

Verified date April 2015
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that everting wound edges while suturing surgical sites will result in more aesthetic scars. Additionally, we also hypothesize that small to moderate wound irregularities present at 3 months will resolve by 6 months after surgery with no intervention


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 2014
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Over 18 years of age

- Able to give informed consent themselves

- Willing to return for follow up visits

Exclusion Criteria:

- Mentally handicapped

- Unable to understand written and oral English

- Incarceration

- Under 18 years of age

- Unwilling to return for follow up

- Pregnant Women

- Wounds less than 3 cm in length

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Intervention

Procedure:
Everted suture technique

Non-everted suture technique


Locations

Country Name City State
United States UC Davis, Department of Dermatology Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Everted versus non-everted suturing techniques Primary outcome measures for this study are the post operative scar width measured at 1 cm from the midline on both sides of the scar. 3 and 6 months No
Primary Mean score of sum of 2 blinded observers POSAS scores The mean summed total of two blinded reviewers Physician Observer Scar Assessment Scale (POSAS) scores for each side of the wound. 3 and 6 months No
Primary Scar measurements (height, width, length) Scar volume will be measured in centimeters on both sides of the wound 3 and 6 months No
Primary Scar induration Scar induration area will be measured in centimeters for both sides of the wound 3 and 6 months No
Primary Scar erythema Scar erythema area will be measured in centimeters for both sides of the wound 3 and 6 months No
Primary Wound contour irregularities Wound contour irregularities will be measured in terms of volume in cubic centimeters via a length, width and height measurement 3 and 6 months No
Primary Stand cone volume The volume of standing cones will be measured via length, width and height measurements in centimeters 3 and 6 months No
Primary Uneven edge measurement The area of uneven edges will be measured via a length x height measurement in centimeters 3 and 6 months No
Primary Hyperpigmentation area areas of hyperpigmentation will be measured via a length x width measurement in centimeters 3 and 6 months No
Secondary Infection Infections occurring anytime during the study period will be recorded up to 6 months Yes
Secondary wound dehiscence incidence of wound infection will be recorded anytime during the study period up to 6 months Yes
Secondary spitting sutures spitting sutures will be counted for each side of the wound at 3 and 6 months 3 and 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study